Tag Archives: ZIOP

Raymond James Sticks to Its Buy Rating for Ziopharm Oncology (ZIOP)

In a report released today, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $5.50. The company’s shares closed last Monday at $3.14, close to its 52-week low

Ziopharm Oncology (ZIOP) Gets a Buy Rating from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $6.50. The company’s shares closed last Monday at $5.21. According to TipRanks.com, Ramakanth has

H.C. Wainwright Maintains a Buy Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $6.50. The company’s shares closed last Monday at $4.11. According to TipRanks.com, Ramakanth is

H.C. Wainwright Sticks to Their Buy Rating for Ziopharm Oncology (ZIOP)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Ziopharm Oncology (ZIOP – Research Report) today and set a price target of $5.50. The company’s shares closed yesterday at $4.41. Ramakanth observed: “We have updated our model to reflect

A Director at Ziopharm Oncology is Exercising Options

Today it was reported that a Director at Ziopharm Oncology (ZIOP – Research Report), James Anthony Cannon, exercised options to buy 15,000 ZIOP shares at $0.70 a share, for a total transaction value of $10.5K. The options were close to

H.C. Wainwright Reiterates Their Buy Rating on Ziopharm Oncology

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP), with a price target of $5.50. The company’s shares closed on Friday at $4.37. Ramakanth wrote: “We note that the biopsy